HA
KNSA icon

HHLR Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

HHLR Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,582,635
Closed -$31.3M – 52
2024
Q4 		$31.3M Hold
1,582,635
– – 1.08% 15
2024
Q3 		$39.6M Sell
1,582,635
-1,561,921
-50% -$38M 0.87% 14
2024
Q2 		$58.7M Buy
3,144,556
+8,821
+0.3% +$165K 1.45% 10
2024
Q1 		$61.9M Buy
+3,135,735
New +$61.2M 1.34% 13
2023
Q4 		– Sell
-698,741
Closed -$12.1M – 56
2023
Q3 		$12.1M Hold
698,741
– – 0.27% 33
2023
Q2 		$9.84M Sell
698,741
-319,350
-31% -$4.27M 0.21% 36
2023
Q1 		$11M Sell
1,018,091
-1,605,833
-61% -$21.2M 0.19% 42
2022
Q4 		$39.3M Sell
2,623,924
-296,099
-10% -$4.31M 0.83% 21
2022
Q3 		$37.5M Hold
2,920,023
– – 0.99% 21
2022
Q2 		$28.3M Hold
2,920,023
– – 0.61% 25
2022
Q1 		$29M Hold
2,920,023
– – 0.61% 25
2021
Q4 		$34.4M Hold
2,920,023
– – 0.53% 29
2021
Q3 		$33.3M Hold
2,920,023
– – 0.44% 35
2021
Q2 		$40.7M Hold
2,920,023
– – 0.42% 38
2021
Q1 		$54M Hold
2,920,023
– – 0.53% 27
2020
Q4 		$51.6M Hold
2,920,023
– – 0.41% 34
2020
Q3 		$44.7M Buy
2,920,023
+476,190
+19% +$8.94M 0.34% 32
2020
Q2 		$62.3M Buy
2,443,833
+547,945
+29% +$11.4M 0.57% 29
2020
Q1 		$29.3M Hold
1,895,888
– – 0.4% 32
2019
Q4 		$21M Buy
1,895,888
+28,266
+2% +$246K 0.26% 35
2019
Q3 		$15.9M Buy
1,867,622
+31,734
+2% +$351K 0.22% 46
2019
Q2 		$24.9M Hold
1,835,888
– – 0.56% 27
2019
Q1 		$33.2M Buy
1,835,888
+447,000
+32% +$8.63M 0.92% 20
2018
Q4 		$39M Buy
+1,388,888
New +$29M 1.62% 13

Other funds holding KNSA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HHLR Advisors's KNSA Position: Q1 2025 in Review

HHLR Advisors sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2025, closing a stake of 1,582,635 shares — an estimated $31.3M sold.

HHLR Advisors first reported a position in KNSA in Q4 2018 and held it in 24 quarters. The position peaked at $62.3M in Q2 2020. 176 funds tracked by Wall St. Rank hold KNSA as of Q1 2025.

  • HHLR Advisors reported no remaining Kiniksa Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • HHLR Advisors sold 1,582,635 Kiniksa Pharmaceuticals shares in Q1 2025, an estimated $31.3M.
  • HHLR Advisors first reported a position in Kiniksa Pharmaceuticals in Q4 2018 and held it in 24 quarters.
  • HHLR Advisors's Kiniksa Pharmaceuticals position peaked at $62.3M in Q2 2020.
  • 176 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2025.

Based on HHLR Advisors's 13F filing for Q1 2025, filed 15 May 2025.